ArticleThe American journal of case reports2025
Complex Ocular Adverse Events Following Oxaliplatin Treatment: A Case Report.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ocular toxicities associated with anticancer drug therapy in Asian patients: a literature review and practical management recommendations for non-ophthalmologic settings.International journal of clinical oncology · 2026Review
- Transient monocular vertical hemifield loss as a rare acute oxaliplatin-induced ophthalmological side effect: a case report and review of the literature.Therapeutic advances in drug safety · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Ocular adverse events related to systemic chemotherapy are relatively rare and often underrecognized in clinical practice. We describe a unique case of severe ocular toxicity associated with oxaliplatin-based chemotherapy, presenting as multiple iris cysts, anterior chamber inflammation, retinal detachment, and lens opacity, ultimately resulting in significant vision loss. CASE REPORT A 47-year-old woman with adenocarcinoma of the esophagogastric junction underwent laparoscopic radical gastrectomy on March 4, 2024. Postoperatively, she was started on adjuvant oxaliplatin-based chemotherapy on April 7, 2024. After completing 3 cycles by May 18, 2024, she developed acute bilateral vision loss. Ophthalmologic evaluation revealed multiple iris cysts, anterior chamber inflammation, exudative retinal detachment, and bilateral dense cataracts. Laboratory investigations demonstrated markedly elevated systemic and aqueous humor IL-6 levels, while orbital CT and MRI excluded ocular metastasis. The patient was initially prescribed oral prednisone, but treatment was unsuccessful due to poor adherence. Subsequently, her regimen was modified to oxaliplatin monotherapy. Surgical interventions were performed in both eyes, leading to partial restoration of vision. However, postoperative examinations continued to show persistent retinal detachment and iris cysts, indicating incomplete recovery. CONCLUSIONS This case underscores the potential for oxaliplatin to induce severe and complex ocular toxicities, mimicking metastatic or inflammatory ocular diseases. Early recognition, comprehensive ophthalmologic evaluation, and interdisciplinary collaboration are essential to distinguish drug-induced events from tumor-related manifestations. Moreover, prompt adjustment of chemotherapy and timely ophthalmic intervention can mitigate irreversible visual impairment. Increased awareness of such complications can aid clinicians in tailoring management strategies and improving quality of life in patients receiving oxaliplatin-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.